Real-world treatment and survival of patients with advanced non-small cell lung Cancer: a German retrospective data analysis
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Real-world treatment and survival of patients with advanced non-small cell lung Cancer: a German retrospective data analysis
Authors
Keywords
-
Journal
BMC CANCER
Volume 20, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-03-31
DOI
10.1186/s12885-020-06738-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Real-world insulin therapy in German type 2 diabetes mellitus patients: patient characteristics, treatment patterns, and insulin dosage
- (2019) Thomas Wilke et al. Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
- Utilization of Molecular Testing and Survival Outcomes of Treatment with First- or Second-line Tyrosine Kinase Inhibitors in Advanced Non-small Cell Lung Cancer in a Dutch Population
- (2018) ANTICANCER RESEARCH
- Treatment decisions, clinical outcomes, and pharmacoeconomics in the treatment of patients with EGFR mutated stage III/IV NSCLC in Germany: an observational study
- (2018) Wolfgang Schuette et al. BMC CANCER
- Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated With First-line Therapies for Medicare Patients 65 Years and Older With Advanced Non–small-cell Lung Cancer: A Retrospective Study
- (2018) Marisa A. Bittoni et al. Clinical Lung Cancer
- Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated With Second-Line Therapies for Medicare Patients With Advanced Non–Small-Cell Lung Cancer
- (2018) Ashwini Arunachalam et al. Clinical Lung Cancer
- Utilization of genomic testing in advanced non-small cell lung cancer among oncologists in the Veterans Health Administration
- (2018) Jennifer Arney et al. LUNG CANCER
- Real-world utilization of molecular diagnostic testing and matched drug therapies in the treatment of metastatic cancers
- (2018) Anita Chawla et al. JOURNAL OF MEDICAL ECONOMICS
- OUP accepted manuscript
- (2018) ANNALS OF ONCOLOGY
- Projections in Breast and Lung Cancer Mortality among Women: A Bayesian Analysis of 52 Countries Worldwide
- (2018) Juan Carlos Martín-Sánchez et al. CANCER RESEARCH
- Molecular testing and treatment patterns for patients with advanced non-small cell lung cancer: PIvOTAL observational study
- (2018) Dae Ho Lee et al. PLoS One
- Real-world EGFR testing in patients with stage IIIB/IV non-small-cell lung cancer in North China: A multicenter, non-interventional study
- (2018) Ying Cheng et al. Thoracic Cancer
- Lung Cancers: Molecular Characterization, Clonal Heterogeneity and Evolution, and Cancer Stem Cells
- (2018) Ugo Testa et al. Cancers
- Molecular profiling in Italian patients with advanced non-small-cell lung cancer: An observational prospective study
- (2017) Elisa Gobbini et al. LUNG CANCER
- Real-world first-line treatment and overall survival in non-small cell lung cancer without known EGFR mutations or ALK rearrangements in US community oncology setting
- (2017) Amy P. Abernethy et al. PLoS One
- Oncogenic driver mutations, treatment, and EGFR-TKI resistance in a Caucasian population with non-small cell lung cancer: survival in clinical practice
- (2017) Martin Faehling et al. Oncotarget
- Non–Small Cell Lung Cancer
- (2017) David S. Ettinger et al. Journal of the National Comprehensive Cancer Network
- Real-world treatment patterns for patients receiving second-line and third-line treatment for advanced non-small cell lung cancer: A systematic review of recently published studies
- (2017) Jessica Davies et al. PLoS One
- 441O Preliminary safety and clinical activity of erlotinib plus atezolizumab from a Phase Ib study in advanced NSCLC
- (2016) B.B.Y. Ma et al. ANNALS OF ONCOLOGY
- The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer
- (2016) Peter Goldstraw et al. Journal of Thoracic Oncology
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- (2016) Roy S Herbst et al. LANCET
- Lung cancer: Biology and treatment options
- (2015) Hassan Lemjabbar-Alaoui et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- Real-world chemotherapy treatment patterns in metastatic non-small cell lung cancer: Are patients undertreated?
- (2015) Adrian G. Sacher et al. CANCER
- Outcomes and resource use of non-small cell lung cancer (NSCLC) patients treated with first-line platinum-based chemotherapy across Europe: FRAME prospective observational study
- (2015) Denis Moro-Sibilot et al. LUNG CANCER
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer
- (2014) K. M. Kerr et al. ANNALS OF ONCOLOGY
- ROS1expression and translocations in non-small-cell lung cancer: clinicopathological analysis of 1478 cases
- (2014) Arne Warth et al. HISTOPATHOLOGY
- Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
- (2014) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology
- (2013) Neal I. Lindeman et al. Journal of Thoracic Oncology
- Real-World Effectiveness of Systemic Agents Approved for Advanced Non-Small Cell Lung Cancer: A SEER-Medicare Analysis
- (2013) T. K. Owonikoko et al. ONCOLOGIST
- A Genomics-Based Classification of Human Lung Tumors
- (2013) Science Translational Medicine
- Targeted therapies in non-small cell lung carcinoma: what have we achieved so far?
- (2013) Fadi S. Farhat et al. Therapeutic Advances in Medical Oncology
- ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers
- (2012) Kristin Bergethon et al. JOURNAL OF CLINICAL ONCOLOGY
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
- (2012) Rafael Rosell et al. LANCET ONCOLOGY
- Global cancer statistics
- (2011) Ahmedin Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Genotype-driven therapies for non-small cell lung cancer: focus on EGFR, KRAS and ALK gene abnormalities
- (2011) Elizabeth M. Gaughan et al. Therapeutic Advances in Medical Oncology
- Consensus for EGFR Mutation Testing in Non-small Cell Lung Cancer: Results from a European Workshop
- (2010) Robert Pirker et al. Journal of Thoracic Oncology
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started